Neurocrine Bio. (NBIX) PT Raised to $120 at SVB Leerink
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $174.26 +3.87%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
SVB Leerink analyst Marc Goodman raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $120.00 (from $105.00) while maintaining a Market Perform rating.
You May Also Be Interested In
- Neurocrine starts CAH drug trial in children under age 4
- Integrafin Holdings Plc (IHP:LN) PT Raised to GBP4.75 at Deutsche Bank
- Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
